Announced
Financials
Tags
Private Equity
treatment development
therapeutic peptides
France
Biotechnology
Acquisition
Private
Single Bidder
Cross Border
Pending
Majority
Friendly
Synopsis
AstraZeneca, a pharmaceutical company, agreed to acquire Amolyt Pharma, a global, clinical-stage biopharmaceutical company, from Sofinnova Partners, a European life sciences venture capital firm, and EQT Life Sciences, a healthcare investor, for $1.05bn. "Congratulations to the Amolyt team on its proposed acquisition by AstraZeneca. Leading Amolyt’s Series C financing round in January 2023 was an honor. This milestone demonstrates Sofinnova's investment thesis in action, showcasing our commitment to supporting innovative European companies during their critical growth stage. In Amolyt's case, it exemplifies our commitment to supporting a company developing groundbreaking solutions in a later stage of development for rare disease patients,” Cédric Moreau, Sofinnova Partner.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.